GlassScriptPhysician profile
Michael Shane Hord
NPI 1205864626
$12,139.57
in general payments reported to CMS, 2019-2025
49 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $1,564 · 2021: $2,069 · 2022: $1,790 · 2023: $1,839 · 2024: $1,800 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,455.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,483.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,483.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,318.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $895.04 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $858.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $717.88 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $563.50 | 2021-2025 | |
| Pfizer INC. | $543.03 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $443.47 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Amgen INC. | $320.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $278.42 | 2019-2022 | |
| Axsome Therapeutics, INC. | $248.03 | 2023-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $221.10 | 2020-2021 | |
| Allergan, INC. | $193.37 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $183.73 | 2024-2025 | Zenpep, Vowst |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.